banner
Bcl-2 inhibitor A-1210477, Purity ≥98%
Inquiry

Cat. No.: X23-10-ZQ013

Bcl-2 inhibitor A-1210477, Purity ≥98%

Synonym: 1668553-26-1; A-1210477; 7-(5-((4-(4-(N,N-Dimethylsulfamoyl)piperazin-1-yl)phenoxy)methyl)-1,3-dimethyl-1H-pyrazol-4-yl)-1-(2-morpholinoethyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid; Bcl-2 inhibitor

  • MDL: MFCD28399118
  • CAS Number: 1668553-26-1
  • Compound CID: 66575373
img
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
A-1210477, soluble in warmed DMSO and insoluble in water and ethanol, specifically inhibits the function of the anti-apoptotic proteins, thereby promoting apoptosis in cancer cells. It targets Mcl-1.
Molecular Weight
850.04
Molecular Formula
C46H55N7O7S
Targets
Mcl-1: 26.2 nM
Form
Lyophilized powder
Purity
≥98%
Solubility
Warmed DMSO: 3 mg/mL (3.52 mM); Water: Insoluble; Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
A-1210477 can be used to assess its role in sustaining cancer cell viability and resistance to chemotherapy.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0